Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus.

Frier BM, Ratzki-Leewing A, Harris SB.

Diabetes Obes Metab. 2019 Jul;21(7):1529-1542. doi: 10.1111/dom.13732. Epub 2019 Apr 29. Review.

PMID:
30924567
2.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

3.

Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.

Lo C, Jun M, Badve SV, Pilmore H, White SL, Hawley C, Cass A, Perkovic V, Zoungas S.

Cochrane Database Syst Rev. 2017 Feb 27;2:CD009966. doi: 10.1002/14651858.CD009966.pub2. Review.

4.

Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.

Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, Plank J, Pieber TR, Gerlach FM.

Cochrane Database Syst Rev. 2016 Jun 30;(6):CD012161. doi: 10.1002/14651858.CD012161. Review.

PMID:
27362975
5.

FreeStyle Libre Flash Glucose Self-Monitoring System: A Single-Technology Assessment [Internet].

Bidonde J, Fagerlund BC, Frønsdal KB, Lund UH, Robberstad B.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Aug 21.

6.

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.

Warren E, Weatherley-Jones E, Chilcott J, Beverley C.

Health Technol Assess. 2004 Nov;8(45):iii, 1-57. Review.

7.

Continuous glucose monitoring systems for type 1 diabetes mellitus.

Langendam M, Luijf YM, Hooft L, Devries JH, Mudde AH, Scholten RJ.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD008101. doi: 10.1002/14651858.CD008101.pub2. Review.

8.

Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes.

Chatterjee S, Khunti K, Davies MJ.

Drugs. 2019 Feb;79(2):173-186. doi: 10.1007/s40265-018-1048-6. Review. Erratum in: Drugs. 2019 Jan 31;:. Drugs. 2019 Apr;79(6):685.

PMID:
30623349
9.

Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.

Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A.

Cochrane Database Syst Rev. 2014 Feb 14;(2):CD009122. doi: 10.1002/14651858.CD009122.pub2. Review.

10.

Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.

Singh S, Wright EE Jr, Kwan AY, Thompson JC, Syed IA, Korol EE, Waser NA, Yu MB, Juneja R.

Diabetes Obes Metab. 2017 Feb;19(2):228-238. doi: 10.1111/dom.12805. Epub 2016 Dec 5. Review.

11.

A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.

Heller S, Mathieu C, Kapur R, Wolden ML, Zinman B.

Diabet Med. 2016 Apr;33(4):478-87. doi: 10.1111/dme.13002. Epub 2015 Dec 13.

12.

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.

Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR; BEGIN® Basal-Bolus Type 1 trial investigators.

Diabet Med. 2013 Nov;30(11):1293-7. doi: 10.1111/dme.12243. Epub 2013 Jun 17.

13.

Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA.

Mauricio D, Meneghini L, Seufert J, Liao L, Wang H, Tong L, Cali A, Stella P, Carita P, Khunti K.

Diabetes Obes Metab. 2017 Aug;19(8):1155-1164. doi: 10.1111/dom.12927. Epub 2017 Apr 10.

14.

Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.

Zhou FL, Ye F, Berhanu P, Gupta VE, Gupta RA, Sung J, Westerbacka J, Bailey TS, Blonde L.

Diabetes Obes Metab. 2018 May;20(5):1293-1297. doi: 10.1111/dom.13199. Epub 2018 Jan 24.

15.

Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes prone to severe hypoglycaemia: The HypoAna trial.

Agesen RM, Kristensen PL, Beck-Nielsen H, Nørgaard K, Perrild H, Christiansen JS, Jensen T, Hougaard P, Parving HH, Thorsteinsson B, Tarnow L, Pedersen-Bjergaard U.

Diabetes Metab. 2016 Sep;42(4):249-55. doi: 10.1016/j.diabet.2016.03.001. Epub 2016 Apr 7.

PMID:
27068361
16.

Understanding the safety of the new ultra long acting basal insulin.

Ramachandran A, Gupta V, Kesavadev J, Kalra S.

J Assoc Physicians India. 2014 Jan;62(1 Suppl):35-42.

PMID:
25330630
17.

Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians.

Brod M, Rana A, Barnett AH.

Curr Med Res Opin. 2012 Dec;28(12):1947-58. doi: 10.1185/03007995.2012.743457. Epub 2012 Nov 14.

PMID:
23150950
18.

Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.

Liu SC, Tu YK, Chien MN, Chien KL.

Diabetes Obes Metab. 2012 Sep;14(9):810-20. doi: 10.1111/j.1463-1326.2012.01606.x. Epub 2012 Apr 29. Review.

PMID:
22486990
19.

Treat-to-target trials: uses, interpretation and review of concepts.

Garber AJ.

Diabetes Obes Metab. 2014 Mar;16(3):193-205. doi: 10.1111/dom.12129. Epub 2013 Jun 14. Review.

20.

Innovative insulins--where do analogues fit?

Phillips LK, Phillips PJ.

Aust Fam Physician. 2006 Dec;35(12):969-73. Review.

PMID:
17149471

Supplemental Content

Support Center